The Comprehensive Package

It is widely recognised that the economic downturn has taken a turn for the better; this can be demonstrated across a number of industries, pharmaceutical development being one.

In the last two years, new chemical entity (NCE) approvals have risen to an extent not seen since the early 1990s. This is encouraging news for an industry that has gone through a significant period of change. In 2012, the US FDA signed off a total of 58 new drug announcements, an impressive rise on previous years. What is surprising about this figure is the increase in approvals of cold chain products, which made up almost 38% of new drug announcements.

With an influx in specialty pharmaceuticals, and orphan and oncology drugs, as well as flu-related vaccines this figure will continue to rise, and along with it the complexities of the drug product life cycle for compounds with special requirements.

Read more about this here

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients